James F. Oliviero III
2021
In 2021, James F. Oliviero III earned a total compensation of $2.3M as President, Chief Executive Officer and Director at Checkpoint Therapeutics, which was about the same as previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $334,800 |
|---|---|
| Salary | $540,000 |
| Stock Awards | $1,417,570 |
| Total | $2,292,370 |
Oliviero received $1.4M in stock awards, accounting for 62% of the total pay in 2021.
Oliviero also received $334.8K in non-equity incentive plan and $540K in salary.
Rankings
In 2021, James F. Oliviero III's compensation ranked 5,494th out of 12,415 executives tracked by ExecPay. In other words, Oliviero earned more than 55.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,494 out of 12,415 | 56th |
Division Manufacturing | 2,322 out of 5,505 | 58th |
Major group Chemicals And Allied Products | 1,009 out of 2,375 | 58th |
Industry group Drugs | 899 out of 2,096 | 57th |
Industry Pharmaceutical Preparations | 648 out of 1,546 | 58th |
Source: SEC filing on April 29, 2022.
Oliviero's colleagues
We found two more compensation records of executives who worked with James F. Oliviero III at Checkpoint Therapeutics in 2021.
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019